Premorbid aspirin use is not associated with lower mortality in older inpatients with SARS-CoV-2 pneumonia

Article Respiratory System

Aspirin reduces cardiovascular events in patients with pneumonia: a prior event rate ratio analysis in a large primary care database

Fergus Hamilton et al.

Summary: This study demonstrates that aspirin use is associated with reduced ischemic events after pneumonia in a primary care setting, suggesting a potential future clinical role in preventing important complications.

EUROPEAN RESPIRATORY JOURNAL (2021)

添加到收藏夹

Article Critical Care Medicine

Effect of aspirin on deaths associated with sepsis in healthy older people (ANTISEPSIS): a randomised, double-blind, placebo-controlled primary prevention trial

Damon P. Eisen et al.

Summary: The study found that daily low-dose aspirin treatment did not reduce deaths associated with sepsis in community dwelling older adults. The findings do not support the use of aspirin as a primary prevention strategy to reduce the burden of sepsis in this population.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹

Letter Cardiac & Cardiovascular Systems

Meta-Analysis of the Effect of Aspirin on Mortality in COVID-19

Husam M. Salah et al.

AMERICAN JOURNAL OF CARDIOLOGY (2021)

添加到收藏夹

Article Hematology

Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis

Matthew L. Meizlish et al.

Summary: In this study of hospitalized COVID-19 patients, intermediate-dose anticoagulation and aspirin treatment were each associated with a significantly lower cumulative incidence of in-hospital death as shown by propensity score matching and multivariable regression analysis.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹

Letter Geriatrics & Gerontology

Should We Prescribe Antibiotics in Older Patients Presenting COVID-19 Pneumonia?

Geoffrey Odille et al.

JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of low-dose aspirin on mortality and viral duration of the hospitalized adults with COVID-19

Qiang Liu et al.

Summary: In a study involving adults infected with SARS-Cov-2, it was found that patients using low-dose aspirin (100 mg/day) had significantly lower 30-day and 60-day mortality rates compared to those not using aspirin, although there was no significant difference in viral duration between the two groups.

MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration

Thomas F. Osborne et al.

Summary: The study found that pre-diagnosis aspirin prescription was significantly associated with decreased mortality rates for COVID-19 positive Veterans, indicating the potential benefits of aspirin for patients with COVID-19.

PLOS ONE (2021)

添加到收藏夹

Article Infectious Diseases

Fourteen-day survival among older adults with severe infection with severe acute respiratory syndrome coronavirus 2 treated with corticosteroid: a cohort study

Laure Gallay et al.

Summary: In older adults with COVID-19 pneumonia requiring oxygen therapy, corticosteroids were found to significantly improve overall survival at day 14. However, there may be an increased risk of adverse events in patients receiving corticosteroid treatment.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

添加到收藏夹

Article Anesthesiology

Outcomes and Risk Factors for Cardiovascular Events in Hospitalized COVID-19 Patients

Qian Xu et al.

Summary: The study analyzed outcomes and risk factors of cardiovascular events in COVID-19 patients, with a subgroup analysis in African American populations. Patients with cardiovascular events had a significantly higher mortality rate, but there was no significant difference in mortality and length of stay between African American and white patients. Unique risk factors for cardiovascular events were identified in African American patients compared to white patients.

JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA (2021)

添加到收藏夹

Article Virology

Decreased in-hospital mortality associated with aspirin administration in hospitalized patients due to severe COVID-19

Mohammad Haji Aghajani et al.

Summary: The use of aspirin in hospitalized patients with COVID-19 is significantly associated with a decrease in mortality rate, suggesting a potential benefit of aspirin add-on therapy in severe cases. Further prospective randomized controlled trials are needed to confirm the efficacy and safety of aspirin administration in this patient population.

JOURNAL OF MEDICAL VIROLOGY (2021)

添加到收藏夹

Editorial Material Pharmacology & Pharmacy

Low-dose aspirin for early COVID-19: does the early bird catch the worm?

John G. Rizk et al.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)

添加到收藏夹

Article Medicine, General & Internal

Use of aspirin in reduction of mortality of COVID-19 patients: A meta-analysis

Ritika Srivastava et al.

Summary: Aspirin may have a role in reducing mortality in COVID-19 patients, but further clinical evidence is needed to draw a valid conclusion. The meta-analysis showed a lower likelihood of death in the aspirin group compared to the non-aspirin group, although the effect changed after excluding outliers.

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of aspirin on coronavirus disease 2019 A nationwide case-control study in South Korea

Minkook Son et al.

Summary: The study did not find any association between aspirin exposure and COVID-19 infection, complications, or mortality. Multiple statistical analyses and subgroup analysis all yielded consistent results, indicating that aspirin use may not be linked to COVID-19 outcomes. Ongoing randomized controlled trials may provide further insights into the effectiveness of aspirin in COVID-19 patients.

MEDICINE (2021)

添加到收藏夹

Article Geriatrics & Gerontology

Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications

Mariana Alves et al.

Summary: Several cardiovascular drugs have the potential to protect COVID-19 patients, although evidence is primarily based on observational studies and age-specific data is lacking. Most current cardiovascular drugs can be safely continued during COVID-19, but general conditions common in older patients must be considered.

EUROPEAN GERIATRIC MEDICINE (2021)

添加到收藏夹

Editorial Material Cardiac & Cardiovascular Systems